Quarterly ResultMay 18, 2026, 09:02 AM
Evofem Q1 Net Sales $0.9M; Net Loss $5.5M; Expands Global Reach
AI Summary
Evofem Biosciences reported first-quarter 2026 financial results, with net sales increasing to $0.9 million from $0.8 million in the prior year period. The company recorded a net loss of $5.5 million, or $(0.04) per share, compared to a net income of $1.0 million in Q1 2025. Total operating expenses decreased to $5.5 million, partly due to a one-time reduction in R&D expense in the prior year. Evofem is advancing its strategy to diversify revenue through ex-U.S. commercialization, including a new distribution agreement for SOLOSEC in Sub-Saharan Africa and ongoing regulatory review in the UAE for PHEXX and SOLOSEC.
Key Highlights
- Net sales for Q1 2026 increased to $0.9 million, up from $0.8 million in Q1 2025.
- Reported a net loss of $5.5 million, or $(0.04) per basic and diluted share, in Q1 2026.
- Total operating expenses decreased to $5.5 million in Q1 2026 from $6.1 million in Q1 2025.
- Expanded global reach with a distribution agreement for SOLOSEC in Sub-Saharan Africa.
- Advanced patient recruitment in an NIH-funded Phase 4 clinical trial for SOLOSEC.
- Cash and cash equivalents were $1.491 million as of March 31, 2026.
- Total stockholders’ deficit was $(77.630) million as of March 31, 2026.
Price Impact
More from EVFM